Natriumvalproaat Chrono Sandoz (Sodium Valproate)

Sodium valproate raises brain levels of the inhibitory neurotransmitter GABA by inhibiting its breakdown and enhancing its synthesis, while also blocking voltage‑gated sodium channels. These actions calm neuronal over‑activity, which underlies seizures, mood instability, and migraine generation.

The dosage of sodium valproate is individualized. A qualified prescriber determines the appropriate strength, frequency, and titration schedule based on the patient’s condition, age, weight, liver function, and response to therapy.

Sodium valproate is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy unless no safer alternative exists. Use while breastfeeding is also discouraged because the drug passes into breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with carbamazepine or phenytoin, sodium valproate offers broader spectrum seizure control, covering both generalized and focal seizures, and provides mood‑stabilising benefits. However, it carries a higher risk of liver toxicity and weight gain, so clinicians balance efficacy against safety for each patient.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually as whole tablets swallowed with water. It may be taken with or without food, but consistency with meals can help reduce gastrointestinal upset. Follow the prescriber’s instructions regarding timing and dose adjustments.

Serious risks include liver failure, acute pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, thrombocytopenia, and hyperammonemic encephalopathy. Patients should be monitored regularly for signs of these conditions and advised to seek immediate medical attention if symptoms arise.

Individuals with known hypersensitivity to sodium valproate, severe hepatic disease, mitochondrial disorders (e.g., POLG‑related disease), or those who are pregnant without a compelling indication should avoid this medication. The prescriber must evaluate each patient’s medical history before initiating therapy.